VRC-07-523

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameVRC-07-523
Drug Alias NameVRC-07-523-L SVRC-HIVMAB075-00-ABVRC-HIVMAB-075 -00-ABVRC-07-523TMB-380
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CD4
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV InfectionsSexually Transmitted Diseases, Viral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBotswanaUnited StatesPuerto Rico +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Taimed Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTaimed Biologics IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesUniversity Of North Carolina At Chapel Hill
Active IndicationsAcquired Immunodeficiency SyndromeHIV InfectionsSexually Transmitted Diseases, Viral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A